Topoisomerase I inhibitors: camptothecins and beyond

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Nuclear DNA topoisomerase I (TOP1) is a vital human enzyme.
• Camptothecin and its derivatives (irinotecan, topotecan) are potent anticancer drugs targeting TOP1.
• These drugs act as interfacial inhibitors, trapping the TOP1-DNA complex.

Purpose of the Study:

• To review the mechanisms and molecular factors influencing tumor response to TOP1 inhibitors.
• To explore rational combination therapies involving TOP1 inhibitors.
• To understand the role of DNA repair and checkpoint pathways in TOP1 inhibitor efficacy.

Main Methods:

• Literature review of existing research on TOP1 inhibitors.
• Analysis of molecular determinants of tumor response.
• Evaluation of DNA repair and checkpoint pathways.
• Consideration of drug combination strategies.

Main Results:

• TOP1 inhibitors represent a key class of anticancer therapeutics.
• Understanding tumor response mechanisms can guide derivative development.
• Combinations with other drugs may enhance anti-tumor activity and reduce side effects.
• DNA repair and checkpoint pathways are critical in mediating response to TOP1-induced DNA damage.

Conclusions:

• TOP1 inhibitors are essential in cancer therapy, with ongoing development of novel derivatives.
• Further research into molecular determinants and combination therapies is crucial for optimizing treatment outcomes.
• Targeting TOP1-DNA interactions offers a promising strategy for developing more effective and safer anticancer drugs.